Literature DB >> 26905515

Fas/FasL, Bcl2 and Caspase-8 gene polymorphisms in Chinese patients with rheumatoid arthritis.

Aiping Zhu1, Mingjie Wang2, Guoxin Zhou2, Hui Zhang2, Ruiping Liu3,4, Yong Wang5,6.   

Abstract

Apoptosis signals are necessary for maintaining homeostasis and an adequate immune response. Dysregulation of apoptosis-related genes in the immune system has an important impact on autoimmune diseases such as rheumatoid arthritis (RA). Thus, we investigated the association between Fas rs2234767 G/A, FasL rs763110 C/T, Bcl2 rs12454712 T/C, Bcl2 rs17757541 C/G, and Caspase-8 rs1035142 G/T polymorphisms and RA susceptibility in a Chinese population. These five single-nucleotide polymorphisms (SNPs) were studied in a Chinese population consisting of 615 patients with RA and 839 controls. Genotyping was performed using a custom-by-design 48-Plex SNP scan TM kit. Furthermore, we undertook a meta-analysis between FasL rs763110 C/T and RA. This study indicated that Fas rs2234767 and Bcl2 rs17757541 polymorphisms were risk factors for RA. No association was observed between FasL rs763110 C/T, Bcl2 rs12454712 T/C, and Caspase-8 rs1035142 G/T polymorphisms and RA in this study. The results of this meta-analysis suggested no significant association between FasL rs763110 C/T and RA. However, stratification analysis of this meta-analysis indicated that FasL rs763110 C/T increased the risk of Caucasian RA patients. In conclusion, this study demonstrated that Fas rs2234767 G/A and Bcl2 rs17757541 T/C polymorphisms might be associated with an increased risk of RA. This meta-analysis revealed that FasL rs763110 C/T was associated with an increased risk of Caucasian RA patients.

Entities:  

Keywords:  B cell lymphoma 2; Caspase-8; Fas/FasL; Rheumatoid arthritis; Single-nucleotide polymorphism

Mesh:

Substances:

Year:  2016        PMID: 26905515     DOI: 10.1007/s00296-016-3443-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  31 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Association between the CTLA-4, CD226, FAS polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis.

Authors:  Young Ho Lee; Sang-Cheol Bae; Gwan Gyu Song
Journal:  Hum Immunol       Date:  2015-01-30       Impact factor: 2.850

3.  In situ expression of protooncogenes and Fas/Fas ligand in rheumatoid arthritis synovium.

Authors:  H Asahara; T Hasunuma; T Kobata; H Inoue; U Muller-Ladner; S Gay; T Sumida; K Nishioka
Journal:  J Rheumatol       Date:  1997-03       Impact factor: 4.666

4.  Polymorphism of HLA-DRB, -DQA1, and -DQB1 in rheumatoid arthritis in Asian Indians: association with DRB1*0405 and DRB1*1001.

Authors:  V Taneja; M J Giphart; W Verduijn; A Naipal; A N Malaviya; N K Mehra
Journal:  Hum Immunol       Date:  1996-03       Impact factor: 2.850

Review 5.  Pathogenesis of juvenile idiopathic arthritis associated uveitis: the known and unknown.

Authors:  Viera Kalinina Ayuso; Nathalia Makhotkina; Maretta van Tent-Hoeve; Jolanda D F de Groot-Mijnes; Nico M Wulffraat; Aniki Rothova; Joke H de Boer
Journal:  Surv Ophthalmol       Date:  2014-03-29       Impact factor: 6.048

6.  Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis.

Authors:  Ş Kobak; A Berdeli
Journal:  Reumatismo       Date:  2012-12-20

Review 7.  Apoptosis as a therapeutic tool in rheumatoid arthritis.

Authors:  Richard M Pope
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106

8.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.

Authors:  R Watanabe-Fukunaga; C I Brannan; N G Copeland; N A Jenkins; S Nagata
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

9.  Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes.

Authors:  T Nakajima; H Aono; T Hasunuma; K Yamamoto; T Shirai; K Hirohata; K Nishioka
Journal:  Arthritis Rheum       Date:  1995-04

10.  Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR.

Authors:  H Das; T Koizumi; T Sugimoto; S Chakraborty; T Ichimura; K Hasegawa; R Nishimura
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

View more
  6 in total

1.  [Danggui Niantong decoction induces apoptosis by activating Fas/caspase-8 pathway in rheumatoid arthritis fibroblast-like synoviocytes].

Authors:  Fan Zhao; Jiayu Li; Qijin Lu; Ensheng Chen; Lixia Yuan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-08-30

Review 2.  The inflammatory role of phagocyte apoptotic pathways in rheumatic diseases.

Authors:  Carla M Cuda; Richard M Pope; Harris Perlman
Journal:  Nat Rev Rheumatol       Date:  2016-08-23       Impact factor: 20.543

3.  Association between Fas/FasL gene polymorphism and musculoskeletal degenerative diseases: a meta-analysis.

Authors:  Donghua Huang; Jinrong Xiao; Xiangyu Deng; Kaige Ma; Hang Liang; Deyao Shi; Fashuai Wu; Zengwu Shao
Journal:  BMC Musculoskelet Disord       Date:  2018-05-07       Impact factor: 2.362

4.  Association between FAS gene -670 A/G and -1377 G/A polymorphisms and the risk of autoimmune diseases: a meta-analysis.

Authors:  Hongwei Yan; Yuxiao Hong; Yunfei Cai
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

5.  FasL (rs763110) gene polymorphism is not associated with susceptibility to rheumatoid arthritis in Croatian population.

Authors:  Marinko Artuković; Marina Ikić Matijašević; Antonio Markotić; Alan Šućur; Danka Grčević; Nataša Kovačić; Darja Flegar; Asja Stipić Marković; Dino Šisl; Irena Artuković; Tomislav Kelava
Journal:  Croat Med J       Date:  2020-12-31       Impact factor: 1.351

6.  The caspase-8/RIPK3 signaling axis in antigen presenting cells controls the inflammatory arthritic response.

Authors:  Salina Dominguez; Anna B Montgomery; G Kenneth Haines; Christina L Bloomfield; Carla M Cuda
Journal:  Arthritis Res Ther       Date:  2017-10-04       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.